microdosing tirzepatide for perimenopause GLP-1 and Menopause: A Hormone-Aware Metabolic Framework Tirzepatide vs Semaglutide for Microdosing

Off-label semaglutide use for BMI under 30 may be appropriate when a patient has metabolic dysfunction, prediabetes, a strong family history of diabetes, or insulin resistance even at a lower weight

However, these safety data come from systemic administration studies

Ozempic (semaglutide) works by mimicking the naturally occurring hormone GLP-1, which regulates blood sugar and appetite

The lead authors of the study are Mahesh Umapathysivam, MBBS, DPhil, an endocrinologist and clinical researcher at Adelaide University in Australia and a former trainee with Gloyn, and Elisa Araldi, PhD, associate professor of medicine and surgery at the University of Parma in Italy and a former trainee with Stoffel

21 ChristensenE